RxDoctor Payments Data

Albert Arceri, PA

Physician Assistant · Albany, NYNPI 1114413697

Payments from drug & device makers

$22,390in general payments, 2019–2025

Across 225 payments — averaging $99.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$19K
  • Johnson & Johnson$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$520
  • Neurocrine Biosciences, Inc.$348
  • Alkermes, Inc.$236
  • Axsome Therapeutics, Inc.$190
  • plus $680 from 7 others

What the payments were for

  • Speaking & faculty fees$16,50074%
  • Travel & lodging$3572%
  • Food & beverage$5,53325%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,390 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$12,199
Medicare patients
17
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl30$43,963
RexultiBrexpiprazole12$19,453
TrintellixVortioxetine Hydrobromide32$18,355
Bupropion XlBupropion Hcl98$2,159
Aripiprazole40$1,909
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$1,505
Methylphenidate ErMethylphenidate Hcl19$1,429
Mirtazapine20$863
Vilazodone Hcl11$761
Buspirone Hcl35$657
Quetiapine Fumarate36$547
Lamotrigine59$541
Duloxetine Hcl48$531
Trazodone Hcl57$393
Hydroxyzine Hcl41$345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$19,364$43,96330 claims
Otsuka America Pharmaceutical, Inc.Rexulti$190$19,45312 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$136$18,35532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →